Get 20% lifetime commission for referring investors to digrin.com
here.
Mersana Therapeutics, Inc. (MRSN) Financials
Stock symbol MRSN is outdated, potentially delisted? Maybe it is available on other exchange?
MRSN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2025 | 62.7 million | 122.2 million |
| June 30, 2025 | 84.6 million | 137.7 million |
| March 31, 2025 | 112.5 million | 143.3 million |
| Dec. 31, 2024 | 144.7 million | 154.2 million |
MRSN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2025 | -3.2 million | 1.2 million |
| June 30, 2025 | -22.6 million | 2.0 million |
| March 31, 2025 | -29.3 million | 2.8 million |
| Dec. 31, 2024 | -19.3 million | 3.3 million |
MRSN Net Income
No data available :(
MRSN Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2025 | 56.4 million | - | 2.3 million |
| June 30, 2025 | 77.0 million | - | 3.3 million |
| March 31, 2025 | 102.3 million | 8.2 million | 4.2 million |
| Dec. 31, 2024 | 134.6 million | 12.2 million | 5.1 million |
MRSN Shares Outstanding
MRSN Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2025 | - | 12.2 million | 6.3 million | - |
| June 30, 2025 | - | 16.2 million | 7.4 million | - |
| March 31, 2025 | - | 18.3 million | 8.9 million | - |
| Dec. 31, 2024 | - | 22.3 million | 8.9 million | - |
MRSN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2025 | 11.0 million | - |
| June 30, 2025 | 3.1 million | 287000 |
| March 31, 2025 | 2.8 million | - |
| Dec. 31, 2024 | 16.4 million | 400000 |
MRSN Revenue by Segment
Graph available only for paid members. Upgrade to see it.
MRSN
Price: $29.08
52 week price:
Earnings Per Share: -13.95 USD
P/E Ratio: -2.11
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 915100
Ebitda: -7.8 millionMarket Capitalization: 147.0 million